CNS Prophylaxis in High-Risk Diffuse Large B-Cell Lymphoma

Administration of high-dose MTX intercalated with cycles of induction immunochemotherapy did not improve outcomes compared with administration after completion of the induction cycles.

Prophylactic high-dose methotrexate (MTX), intrathecal MTX, or both are commonly given in conjunction with induction immunochemotherapy for patients with diffuse large B-cell lymphoma (DLBCL) and risk factors for parenchymal or leptomeningeal central nervous system (CNS) relapse; risk factors include testicular, sinonasal, renal, and adrenal sites of disease. To determine whether timing of MTX administration affects outcomes, investigators conducted an international retrospective analysis of 1384 patients with newly diagnosed DLBCL who were deemed at high risk for CNS relapse.

Patients had received cycles of induction R-CHOP or R-CHOP-like regimens (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) along with hig…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

CNS Prophylaxis in High-Risk Diffuse Large B-Cell Lymphoma

Topics

Reviewing Author